Abstract
Proliferating cell nuclear antigen binding factor (encoded by KIAA0101/ PCLAF) regulates DNA synthesis and cell cycle progression; however, whether the level of KIAA0101 mRNA in lung adenocarcinoma is related to prognosis and tumor immune infiltration is unknown. In patients with lung adenocarcinoma, the differential expression of KIAA0101 was analyzed using the Oncomine, GEPIA, and Ualcan databases. The prognosis of patients with different KIAA0101 expression levels was evaluated using databases such as Prognostan and GEPIA. Tumor immune infiltration associated with KIAA0101 was analyzed using TISIDB. Linkedmics was used to perform gene set enrichment analysis of KIAA0101. KIAA0101 expression in lung adenocarcinoma tissues was higher than that in normal lung tissues. Patients with lung adenocarcinoma with low KIAA0101 expression had a better prognosis than those with high KIAA0101 expression. We constructed the gene regulatory network of KIAA0101 in lung adenocarcinoma. KIAA0101 appeared to play an important role in the regulation of tumor immune infiltration and targeted therapy in lung adenocarcinoma. Thus, KIAA0101 mRNA levels correlated with the diagnosis, prognosis, immune infiltration, and targeted therapy in lung adenocarcinoma. These results provide new directions to develop diagnostic criteria, prognostic evaluation, immunotherapy, and targeted therapy for lung adenocarcinoma.
Highlights
Lung cancer remains one of the most common cancers in men worldwide [1, 2]
After a genome-wide analysis, we identified these 23 genes, including KIAA0101, which were overexpressed in lung adenocarcinoma (LUAD) (Figure 1A, red text genes)
The results showed that when comparing cancer samples with normal samples, KIAA0101 was overexpressed in 17 LUAD datasets, but was not under-expressed in any of the LUAD datasets (Figure 1B)
Summary
In the United States, between 2008 and 2014, the 5-year relative survival rate for lung cancer was only 19% [2]. Lung cancer includes multiple subtypes, and the proportion of lung adenocarcinoma (LUAD) has increased in recent years. Despite significant improvements in chemotherapy and molecular targeted therapy, the survival rate of LUAD is still unsatisfactory. We carried out a study on the relationship between the expression of KIAA0101 and immune escape in lung adenocarcinoma, and further studied the effect of KIAA0101 expression on immunotherapy of lung cancer. Our study showed that overexpression of KIAA0101 promotes immune escape in lung www.aging-us.com adenocarcinoma. Searching for novel molecular biomarkers and improving immunotherapy of tumors in the diagnosis and treatment of LUAD are important [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
